APUS

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Today, 9:06 AMApimeds Pharmaceuticals US plans MindChain Layer 2 blockchain launch in Oct 2026, NILA token to start U.S. trading on licensed Webot Aug 3

Peers: AYTU CPHI RMTI TXMD BGM SCYX CPIX CTOR DERM SCLX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	8.98M
Enterprise Value	8.10M
Income	-40.66M
Sales	0.00M
Book/sh	100.54
Cash/sh	6.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	May 09, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.06
P/C	0.86
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.90
Current Ratio	0.90
Debt/Eq	0.08
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-27.05
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-108.46% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1844.06%
Sales Y/Y TTM	-
EPS Q/Q	-4339.15%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	62.68%
Insider Trans	-
Inst Own	29.74%
Inst Trans	-
ROA	-57.48%
ROE	-65.18%
ROIC	-32.11%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.11%
SMA50	-43.09%
SMA200	-64.23%
Trades

Shs Outstand	1.26M
Shs Float	0.56M
Short Float	3.14%
Short Ratio	0.81
Short Interest	0.02M
52W High	59.70 -90.03%
52W Low	5.44 9.37%
Volatility	18.67% 16.41%
ATR (14)	1.29
RSI (14)	31.76
Beta	0.16
Rel Volume	0.88
Avg Volume	21.82K
Volume	7,901

Perf Week	-6.59%
Perf Month	-33.89%
Perf Quarter	-68.35%
Perf Half Y	-62.81%
Perf YTD	-63.72%
Perf Year	-70.98%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	6.29
Price	5.95
Change	-5.41%

Today 08:30AM	MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October (GlobeNewswire) -5.41%
Jul-07-26 09:30PM	Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon (NYSE) -13.66%

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

PresidentMr. Erik C. Emerson

Chief Financial OfficerMr. Erick J. Frim

Founder & Co-CEODr. Vinod Menon

Co-Chief Executive OfficerMr. Sungjoon Chae

Chief Operating OfficerCaptain Sandeep Singh Yadav

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your Finviz experience